



Press release

Stockholm May 10, 2002

Start of third group (of four) in the Diamyd diabetes vaccine trial

Diamyd Medical is starting the third group of 12 patients of the ongoing diabetes vaccine study in parallel in Malmö and Stockholm, with its GAD-based vaccine Diamyd. The ongoing Phase II study involves four groups of 12 patients each.

The study is being monitored by Chiltern in the UK, which has announced that the safety committee has given green light for this group. The first application of the vaccine will be to prevent diabetes patients who are being treated with oral drugs from becoming dependent on having to take insulin injections.

Diamyd Medical's business idea is to identify and develop pharmaceutical projects up to and including Phase II. The project will then be sold or licensed out to a major pharmaceutical company for continued commercialization. Development and marketing of related diagnostic tests and substances are also pursued to promote contacts with researchers and prepare the market for the impending pharmaceutical.

The Company has identified two therapy projects. The most advanced is the diabetes vaccine Diamyd, which is undergoing phase II studies. The Company's other project is a filter for specific elimination of GAD-antibodies. The filter may be used as a complement to vaccination against diabetes as well as for treatment of the neuromuscular disease SMS.

Diamyd Medical's diagnostic work focuses on marketing of its own development, a kit for identifying patients who run the risk of developing insulin-dependent diabetes. Furthermore the active substance in the vaccine, the GAD protein, is marketed to researchers. Recently the production of another diabetes-related protein, IA-2, was started. The Company plans to start sales of this protein by the end of the year.

Diamyd Medical AB (publ) is developing a vaccine for insulin-dependent diabetes and is traded on the NGM list

For further information, contact Anders Essen-Möller, Diamyd Medical AB, Tel: +46 8-661 00 26, 661 12 25, fax: +46 8-661 63 68 or email: info@diamyd.com web site: www.diamyd.com

No guarantees are given or implied for the accuracy of statements on historical or future results.